Evaluation of probable or possible dementia with Lewy bodies using 123I-IMP brain perfusion SPECT, 123I-MIBG, and 99mTc-MIBI myocardial SPECT

Journal of Nuclear Medicine

Volumn 48, Issue 10, 2007, Pages 1641-1650

  Inui, Yoshitaka ^a,c   Toyama, Hiroshi ^a   Manabe, Yuta ^a   Sato, Takahisa ^a   Sarai, Masayoshi ^a   Kosaka, Kenji ^b   Iwata, Nakao ^a   Katada, Kazuhiro ^a  

^a FUJITA HEALTH UNIVERSITY   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

3 dimensional stereotactic surface projection; 123I MIBG; 99mTc MIBI; Dementia with Lewy bodies; Gated SPECT

Indexed keywords

IOFETAMINE I 123; METAIODOBENZYLGUANIDINE I 123; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BRAIN PERFUSION; BRAIN REGION; CLINICAL ARTICLE; CONTROLLED STUDY; DEMENTIA; DISEASE SEVERITY; ELECTROCARDIOGRAPHY; FEMALE; GATED IMAGING; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; ISCHEMIA; LEWY BODY; MALE; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

3-IODOBENZYLGUANIDINE; AGED; AGED, 80 AND OVER; BRAIN; FEMALE; HEART; HUMANS; IMAGING, THREE-DIMENSIONAL; IOFETAMINE; LEWY BODY DISEASE; MALE; PERFUSION; PROGNOSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TECHNETIUM TC 99M SESTAMIBI; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 35348847851     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.107.042143     Document Type: Article

References (39)

1. McKeith I, Mintzer J, Aarsland D, et al. Dementia with Lewy bodies. Lancet Neurol. 2004;3:19-28.
2. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathological diagnoses of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. Neurology. 1996;47:1113-1124.
3. McKeith IG, Del Ser T, Spano P, et al. Efficacy of rivastingmine in dementia with Lewy bodies: a randomized double blind, placebo-controlled intermation study. Lancet. 2000;356:2031-2036.
4. McKeith I, Fairbairn A, Perry R, Thompson P, Perry E. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. Br J Psychiatry. 1992;305:673-678.
5. Mega MS, Masterman DL, Benson DF, et al. Dementia with Lewy bodies: reliability and validity of clinical and pathologic criteria. Neurology. 1996;47:1403-1409.
6. Luis CA, Barker WW, Gajarai K, et al. Sensitivity and specificity of three clinical criteria for dementia with Lewy bodies in an autopsy-verified sample. Int J Geriatr Psychiatry. 1999;14:526-533.
7. Holmes C, Cairns N, Lantos P, Mann A. Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies. Br J Psychiatry. 1999;174:45-50.
8. McKeith IG, Ballard CG, Perry RH, et al. Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology. 2000;54:1050-1058.
9. Albin RL, Minoshima S, D'Amato CJ, et al. Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology. 1996;47:462-466.
10. Ishii K, Yamaji S, Kitagaki H, Immamura T, Hirono N, Mori E. Regional cerebral blood flow difference between dementia with Lewy bodies and AD. Neurology. 1999;53:413-416.
11. Minoshima S, Foster NL, Sima AA, Frey KA, Albin RL, Kuhl DE. Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol. 2001;50:358-365.
12. Lobotesis K, Fenwick JD, Phipps A, et al. Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology. 2001;56:643-649.
13. 99mTc-HMPAO SPET changes in dementia with Lewy bodies and Alzheimer's disease using statistical parametric mapping. Eur J Nucl Med Mol Imaging. 2002;29:615-622.
14. Mizumura S, Kumita S, Cho K, et al. Development of quantitative analysis method for stereotactic brain image: assessment of reduced accumulation in extent and severity using anatomical segmentation. Ann Nucl Med. 2003;17:289-295.
15. 123I-meta- iodobenzylguanidine (MIBG) uptake in dementia with Lewy bodies: comparison with Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2001;70:781-783.
16. 123I]MIBG myocardial scintigraphy in the distinction between dementia of the Alzheimer's-type and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2001;71:583-588.
17. 123I]MIBG) myocardial scintigraphy in differentiating between Alzheimer's disease and dementia with Lewy bodies. Intern Med. 2003;42:686-690.
18. Orimo S, Amino T, Itoh Y, et al. Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease. Acta Neuropathol (Berl). 2005;109:583-588.
19. 123I]MIBG myocardial scintigraphy in distinguishing between dementia with Lewy bodies and Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2006;33:248-253.
20. Walker MP, Ayre GA, Cummings JL, et al. The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment scale: two methods to assess fluctuating confusion in dementia. Br J Psychiatry. 2000;177:252-256.
21. Minoshima S, Berger KL, Lee KS, Mintun MA. An automated method for rotational correction and centering of three-dimensional functional brain images. J Nucl Med. 1992;33:1579-1585.
22. Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med. 1995;36:1238-1248.
23. Germano G, Erel J, Kait H, et al. Quantitative LVEF and qualitative regional function from gated thallium-201 perfusion SPECT. J Nucl Med. 1997;38:749-754.
24. 99mTc-HMPAO single-photon emission computed tomography study of Lewy body disease. J Neurol. 1997;244:349-359.
25. Cordery RJ, Tyrrell PJ, Lantos PL, Rossor MN. Dementia with Lewy bodies studied with positron emission tomography. Arch Neurol. 2001;58:505-508.
26. Londos E, Passant U, Brun A, Rosen I, Risberg J, Gustafson L. Regional cerebral blood flow and EEG in clinically diagnosed dementia with Lewy bodies and Alzheimer's disease. Arch Gerontol Geriatr. 2003;36:231-245.
27. Merlet P, Valette H, Dubois-Rande JL, et al. Prognostic value of metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med. 1992;33:471-477.
28. 123I-MIBG uptake and increased clearance in various cardiac diseases. Nucl Med Commun. 1994;15:317-323.
29. 123I-MIBG scintigraphy as a pathophysiological indicator in the assessment of Parkinson's disease and related disorders: it can be a specific marker for Lewy body disease. Ann Nucl Med. 2004;18:453-461.
30. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies. Neurology. 2005;65:1-10.
31. 99mTc-ECD brain SPECT scans in adults. J Nucl Med. 2000;41:1456-1464.
32. Ito H, Inoue K, Goto R, et al. Database of normal human cerebral blood flow measured by SPECT. I. Comparison between I-123-IMP, Tc-99m-HMPAO, and Tc-99m-ECD as referred with O-15 labeled water PET and voxel-based morphometry. Ann Nucl Med. 2006;20:131-138.
33. Iwanaga K, Wakabayashi K, Yoshimoto M, et al. Lewy body-type degeneration in cardiac plexus in Parkinson's and incidental Lewy body diseases. Neurology. 1999;52:1269-1271.
34. Orimo S, Oka T, Miura H, et al. Sympathetic cardiac denervation in Parkinson's disease and pure autonomic failure but not in multiple system atrophy. J Neurol Neurosurg Psychiatry. 2002;73:776-777.
35. Kuzuhara S, Yoshimura M. Clinical and neuropathological aspects of diffuse Lewy body disease in the elderly. Adv Neurol. 1993;60:464-469.
36. Hely MA, Reid WG, Halliday GM, et al. Diffuse Lewy body disease: clinical features in nine cases without coexistent Alzheimer's disease. J Neural Neurosurgery Psychiatry. 1996;60:531-538.
37. 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol. 2007;6:305-313.
38. Lekakis J, Antoniou A, Vassilopoulos N, et al. I-123 metaiodobenzylguanidine-thallium-201 mismatch following myocardial infarction. Clin Cardiol. 1994;17:21-25.
39. 123I-MIBG myocardial scintigraphy as a noninvasive screen for the diagnosis of coronary artery spasm. J Nucl Cardiol. 1998;5:591-597.